Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.37 |
| ▸ | GLRB | P48167 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5671594 | 1.00 | ADAM10 (0.45) | ADAM10MMP3MMP2MMP9DRD4 | |
| SCHEMBL5670609 | 0.88 | ADAM10 (0.46) | ADAM10MMP3MMP2DRD4HCRTR2 | |
| SCHEMBL5670613 | 0.88 | ADAM10 (0.46) | ADAM10MMP3MMP2DRD4HCRTR2 | |
| SCHEMBL5669604 | 0.87 | MMP2 (0.41) | ADAM10MMP3MMP2TSHRHCRTR2 | |
| SCHEMBL5670595 | 0.87 | RBP4 (0.50) | ADAM10MMP2HCRTR2CYP2D6 | |
| SCHEMBL5669935 | 0.85 | MEN1 (0.47) | MMP2MMP9DRD4TSHRHCRTR2 | |
| SCHEMBL5670448 | 0.85 | MEN1 (0.47) | MMP2MMP9DRD4TSHRHCRTR2 | |
| SCHEMBL5670753 | 0.85 | MMP3 (0.38) | ADAM10MMP3MMP2MMP9ALDH1A1 | |
| SCHEMBL5670525 | 0.84 | MMP2 (0.47) | MMP3MMP2CHRM4ALDH1A1CYP1A2 | |
| SCHEMBL5669731 | 0.82 | ADAM10 (0.48) | ADAM10MMP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | ADAM10 108/4885MMP3 17/4885MMP2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.